1035229-34-5Relevant articles and documents
SMYD2 INHIBITORS
-
, (2016/02/20)
The present disclosure generally relates to compounds having cellular anti-proliferative activities, and more particularly relates to compounds which inhibit the activity of human SMYD2, a SET and MYND domain-containing protein lysine methyltransferase.
NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA-2 RECEPTORS
-
Page/Page column 50-51, (2010/04/03)
The present invention relates to named compounds of the formula (I) having both M3 receptor antagonist and β2 agonist activity; compositions comprising such compounds; the use of such compounds in therapy (such as respiratory tract disorders); and a metho
AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES
-
Page/Page column 86, (2008/12/06)
The present invention provides compounds of formula (I), wherein k, Ar, R2, R3, R4, R5, R4', R5', R6, R7, A, D, m and E are as defined in the specification, processes